Groundbreaking real-world evidence supports nirsevimab’s role against RSV In a significant step forward for pediatric infectious disease prevention, a large real-world study published in the Journal of Infection provides fresh evidence that the long-acting monoclonal antibody nirsevimab (Beyfortus) offers protection against respiratory syncytial virus (RSV) infection in children. The findings, drawn from diverse clinical settings,…